You can spend months trying medication after medication and still feel like nothing has shifted. A person in their late 30s can do everything right, take sertraline as prescribed, then venlafaxine, then an augmentation strategy, and still wake at 4 a.m. with the same heavy, unfinished feeling that cancels plans before the day even starts. That's the lived reality of treatment-resistant depression, and it's exactly the point where Spravato for depression starts to matter.
When Standard Antidepressants Are Not Enough
A lot of people arrive at this point feeling worn down rather than surprised. They've already done the routine, the dose changes, the follow-ups, the hopeful waiting, and each round has ended with the same quiet disappointment. The grief is real, because every failed trial costs time, energy, and trust.
The pattern patients describe
Clinically, treatment resistance means inadequate response to at least two antidepressants of adequate dose and duration. That definition matters because it separates true nonresponse from a medication that was stopped early, under-dosed, or abandoned only because of side effects. It also explains why the word “failed” can feel harsh to patients, even when it's just a technical way of saying the brain hasn't responded enough yet.
Spravato was developed for adults in this exact situation. It isn't a first-step medicine, and it isn't meant to replace therapy, sleep, or a careful diagnosis review. It's a different kind of intervention for when the standard toolbox has already been used thoughtfully and the depression is still there.
Practical rule: if you've been treated with two or more antidepressants and the core symptoms are still shaping your days, you're in the group clinicians usually mean when they talk about TRD.
That's why the conversation often shifts from “What else can we try?” to “What mechanism have we not tried yet?” Spravato changes that conversation because it works through a different brain system than the usual serotonin-based approach. For many patients, that's the first time a psychiatrist can offer something that isn't just another version of the same strategy.
What Spravato Actually Is and How It Works
A patient usually hears about Spravato after several antidepressants have already fallen short, and the next question is simple: what is it, really? Spravato is the brand name for esketamine nasal spray, an intranasal, non-competitive NMDA receptor antagonist for adults with treatment-resistant depression. Janssen's announcement of the FDA approval described it as the first NMDA receptor antagonist approved for this use (Janssen announcement). The FDA label also states that it can be used as monotherapy or with an oral antidepressant in adults who have not responded adequately to at least two oral antidepressants (FDA label).
Why this medicine feels different
Traditional SSRIs and SNRIs mainly work through serotonin or norepinephrine, and they often need time before a patient can tell whether anything has changed. Esketamine works through glutamate signaling at the NMDA receptor, so it comes at depression through a different pathway. That difference is why clinicians usually describe it as a separate option, not just a stronger version of the usual medications.
The medicine is given as a nasal spray, not an IV infusion. In practice, the dose used is typically 56 mg or 84 mg, and each session happens in a restricted clinical setting with observation because the drug can cause temporary dissociation, sedation, and blood-pressure changes (FDA label). The supervised setting is part of how the treatment is delivered, not an extra layer added afterward.
What it does and doesn't promise
Spravato does not promise to erase depression overnight. It offers a different biological route when standard antidepressants have not been enough. For some people, it may act like a bridge while the rest of the treatment plan is still being built, and for others it becomes part of longer-term maintenance. The tradeoff is that it requires an office-based process, careful monitoring, and a realistic conversation about cost and insurance before treatment begins.
Who Qualifies and Who Should Avoid It
A person may look like a good candidate on paper, yet still need a careful review before starting. Spravato is for adults with major depressive disorder who have had inadequate response to at least two oral antidepressants from different classes, and the FDA label also includes adults with depressive symptoms in acute suicidal crises when clinically appropriate. Here, “inadequate response” means the depression did not improve enough to count as a real clinical response, not just that side effects were unpleasant or the medication was stopped early (FDA label).
The REMS setting is part of eligibility
Spravato is only available through the FDA-required REMS program, so patients must be enrolled before treatment and receive the medication under direct observation in a restricted setting, not at home (REMS label). That supervised setup is part of the treatment itself, like having a fire drill with staff present instead of sending people off with a checklist. After each dose, the label requires at least 2 hours of post-dose monitoring and blood pressure checks during that period (monitoring label).
Who needs a careful pause first
Some medical histories call for extra caution before treatment begins. That includes uncontrolled hypertension, aneurysmal vascular disease, arteriovenous malformation, or a history of intracerebral hemorrhage. Pregnancy also calls for a direct risk discussion, and a current substance use disorder that has not been stabilized deserves careful review because this treatment must be handled in a tightly supervised clinical framework.
The practical question many people ask is whether their past treatment trials really count. Bring the names of prior antidepressants, the doses used, and how long each was taken, because that gives the clinician a clearer map than a vague memory of “nothing helped.”
A well-run intake process can make that step easier, and some clinics now offer 24/7 patient intake for clinics, which helps when someone is ready to ask for help outside normal office hours.
What a Spravato Session Really Looks Like
A Spravato appointment feels closer to a monitored medical visit than a quick pharmacy stop. You arrive, check in, and the team reviews your blood pressure before any dose is given. Then you self-administer the nasal spray while a clinician stays nearby, because the medicine is taken under observation and does not go home with you.
The dosing rhythm
Treatment often starts with an induction phase of 56 mg or 84 mg twice weekly for weeks 1 through 4, then shifts into an optimization phase in weeks 5 through 8 before maintenance. The exact schedule is individualized, but the pattern is easy to remember, more visits early, fewer visits later if benefit holds.
The room is usually quiet and low stimulation. Some people sit in a recliner and describe the session as floaty, dreamy, or a little detached from time. Others mainly notice nausea, mild dissociation, or sounds and body sensations feeling unfamiliar for a while.
You should not drive yourself home after treatment. The medicine can temporarily impair alertness and judgment even after the visit ends.
The monitored period is at least 2 hours after dosing, with blood pressure checks during that window. That is not just routine paperwork, it is part of how supervised Spravato care is set up.
Same-day mood shifts can happen, but many people still feel groggy by the end of the visit and somewhat off for the rest of the day.
For a clinic-level overview of supervised Spravato care, see ketamine and SPRAVATO management at reVIBE.
How Well Spravato Works in Trials and Real Life
A useful way to read the evidence is simple. Spravato helps a meaningful share of people with treatment-resistant depression, but it does not help everyone, and the pattern of benefit can differ across the course of care. In the FDA review, one study found 27.0% of patients receiving intranasal esketamine plus an oral antidepressant were responders at Day 28, compared with 13.3% with placebo plus oral antidepressant (FDA review). That is a real signal, and it also shows why many patients still need a backup plan.
Response is not the same as remission
Response means symptoms improved enough to matter in everyday life. Remission means the depression has fallen to a much lower clinical level. Patients often blur those terms when they read a brochure, but they are different targets.
The larger Spravato program in TRD included more than 1,700 adults across five key trials, with the FDA label noting safety evaluation in 1,709 adults (Janssen announcement). That kind of development program is sizable for psychiatry, where new mechanisms often reach the clinic with a thinner evidence base.
What long-term benefit looks like
Durability is the question patients usually ask after the first round of hopeful talk. A real-world ECHO study in Europe and Israel followed 570 people with severe, chronic TRD and reported a mean MADRS improvement of 14 points by 12 weeks and 17.6 points by 48 weeks, with symptom stability over six months after discontinuation in the post-treatment follow-up group (Janssen EMEA press release). That does not mean every person stays well after stopping. It does show why clinicians talk about Spravato as either a bridge to steadier control or part of longer maintenance, depending on how the patient responds.
In plain terms, some people use it the way you might use physical therapy after an injury, a structured stretch of treatment to get movement back. Others need ongoing sessions to keep the gains from slipping away.
| Trial / Phase | Timepoint | Response Rate (Spravato + oral AD) | Remission Rate (Spravato + oral AD) |
|---|---|---|---|
| FDA primary study | Day 28 | 27.0% | Not provided in verified data |
Side Effects, Safety Monitoring, and Discontinuation
Patients usually feel the side effects during the visit, not days later, so the clinic has to plan around them. The common ones include dissociation, dizziness, nausea, headache, vertigo, and an altered sense of time. Most settle within a couple of hours. That brief window can still feel strange, especially if someone is expecting the session to feel like a standard office medication check.
Monitoring is required for two reasons. Blood pressure can rise after the dose, so the observation period includes blood-pressure checks. Sedation and dissociation can also affect judgment and coordination, which is why patients stay on site and cannot drive themselves home.
The label also calls for caution with uncontrolled hypertension, recent aneurysmal or hemorrhagic events, pregnancy, and active psychosis. Those are situations where the team should pause and compare Spravato with other options before moving ahead.
If the side effects feel more troubling than the depression after the first few sessions, say so directly. The plan may need a different dose, slower timing, a calmer setting, or a different treatment altogether, but that only happens when the team hears what the patient is experiencing.
A structured medication visit can help sort out whether the problem is tolerability, logistics, or a poor fit. For patients comparing treatment options with a clinician, psychiatric medication management support can be part of that conversation.
Spravato Compared to Ketamine and Other Options
Patients usually aren't choosing between “Spravato or nothing.” They're choosing among different paths with different tradeoffs. The clearest comparison is with racemic ketamine infusion, TMS, and ECT, because those are the options most often discussed when depression has already resisted standard treatment.
The practical differences
Spravato is an FDA-approved treatment for TRD, while racemic ketamine is typically used off-label and compounded or administered through cash-pay infusion clinics. That difference affects insurance, monitoring expectations, and how standardized the dose is. TMS is noninvasive and doesn't require anesthesia, while ECT generally requires anesthesia and a more intensive procedural setup.
A helpful starting point is the question patients keep asking in consultation rooms, which treatment is the best fit for urgency, access, and comfort with monitoring? The answer depends on medical history, how quickly symptoms need to improve, and how much time and travel the person can manage.
For people trying to understand the broader ketamine options, how ketamine helps treatment-resistant depression gives useful context for why clinicians sometimes compare these options even when the delivery methods differ.
| Modality | Mechanism | FDA Status | Sessions / Frequency | Anesthesia | Typical Out-of-Pocket |
|---|---|---|---|---|---|
| Spravato | Esketamine, NMDA receptor antagonism | FDA-approved for TRD | Repeated supervised visits | No | Often insurer-dependent |
| Ketamine infusion | Racemic ketamine, off-label use | Not FDA-approved for depression | Clinic-based infusion protocols | No | Often cash-pay |
| TMS | Magnetic stimulation | FDA-cleared for depression | Repeated office sessions | No | Often insurer-dependent |
| ECT | Electrical stimulation under procedural care | FDA-regulated procedure | Repeated sessions | Yes | Often higher procedural exposure |
The point isn't that one option wins every time. It's that the right choice changes with the person, the severity of the illness, and what kind of treatment burden they can realistically carry.
Cost, Insurance, and Authorization
Money is often the first thing people worry about, and that concern is rational. The drug's list price has been described in the range of $600 to $900 per dose, but medication cost is only part of the total because you also have to account for facility time, clinical monitoring, and the REMS infrastructure. In real life, an induction month can run $4,000 to $7,000 before coverage, depending on dose, site fees, and how the clinic bills the visit.
How authorization usually works
Insurance companies usually want proof that the person has tried and not adequately responded to two antidepressants and that treatment is happening at a REMS-certified site. That means the clinic's paperwork matters as much as the prescription itself. A careful appeal packet can make the difference, and clinicians often rely on structured documentation to show medical necessity, especially when the payer asks for records that prove prior failures.
If you're gathering documents, bring your past medication list, approximate dates, dose changes, diagnosis history, and the contact information for your current psychiatrist or therapist if you have one. A strong prior-authorization submission often starts with a clean timeline, and resources like effective appeals for prior authorization can help office staff understand what payers typically look for in a submitted request.
What Phoenix-area patients should ask first
For local patients, the simplest next step is a phone screen and a records review. ReVIBE Mental Health can help with that process and offers Spravato care in the Phoenix metro at reVIBE Mental Health – Chandler, 3377 S Price Rd, Suite 105, Chandler, AZ; reVIBE Mental Health – Phoenix Deer Valley, 2222 W Pinnacle Peak Rd, Suite 220, Phoenix, AZ; reVIBE Mental Health – Phoenix PV, 4646 E Greenway Road, Suite 100, Phoenix, AZ; reVIBE Mental Health – Scottsdale, 8700 E Via de Ventura, Suite 280, Scottsdale, AZ; and reVIBE Mental Health – Tempe, 3920 S Rural Rd, Suite 112, Tempe, AZ. The direct scheduling number is (480) 674-9220.
Spravato insurance guidance can also be reviewed through reVIBE's mental health insurance information, which is useful before you sit down for a consultation. Medicare Part B coverage may apply for eligible patients, and the manufacturer's Spravato withMe copay support can reduce cost for some commercially insured patients to as little as $10 per dose. Uninsured cash-pay pricing varies by clinic and treatment plan, so it's worth asking for a full estimate before the first session.
Bring these four questions to the consultation:
- Timeline: How soon could I realistically start after approval?
- Maintenance: What dose and visit frequency would you expect after the first month?
- Coordination: How will you work with my outside therapist or psychiatrist?
- Costs: What parts of the visit are billed as medication, facility care, or monitoring?
If you're trying to decide whether Spravato fits your depression treatment plan, reVIBE Mental Health can help you sort through eligibility, insurance steps, and what supervised care would look like in day-to-day practice. Visit reVIBE Mental Health to ask about a consultation and see whether a Spravato evaluation makes sense for you.
